Content Type: Article

  • Trademark Licensing

    ARTICLE

    Trademark Licensing

    February 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Sarah Bro

    Partner

    Orange County, Los Angeles

    More insights

  • COVID-19 –  Overview of Government Aid Programs and Rescue Packages in Germany

    COVID-19 – Overview of Government Aid Programs and Rescue Packages in Germany

    ARTICLE / CLIENT ALERT

    COVID-19 – Overview of Government Aid Programs and Rescue Packages in Germany

    19. März 2020

    Read time: 3 min

    Key takeaways
    Overview

    The Coronavirus (COVID-19) and the various measures taken to contain its spread threaten to cause severe damage to the German economy. Companies that are directly or indirectly affected by the outbreak should expect their operating capacity to be reduced and a number of financial consequences. In extreme cases, the COVID-19 crisis could lead to liquidity problems that could threaten the company’s existence and lead to insolvency.

    In depth

    In order to avert these (threatening) liquidity crises for companies, the Federal Government, the European Commission and the state governments have announced comprehensive packages of measures. These include regulations on short-term work compensation, relief for state emergency aid, e.g. liquidity support and risk assumption (e.g. KfW Entrepreneur Loan), reactivation of protective shields (for key companies, among others) as well as fiscal liquidity support for large caps, mid-caps and SMEs.

    We have compiled a checklist with an overview of all major aid programs and rescue umbrellas, which we would be happy to share with you and help you to review relevant programs and applications.

    Our multidisciplinary COVID-19 team of highly qualified lawyers from the fields of restructuring, insolvency and corporate law, banking and finance, antitrust and state aid, tax, labour, healthcare, life science and public law, is well placed to advise you on restructuring issues resulting from the COVID-19 crisis.

    With over 20 offices worldwide and over 130 lawyers at our four locations in Germany, we can offer all-round support from the expert who has a perfect command of your legal problems and the market in which you find yourself.

    Feel free to contact us at any time if required. We will also be happy to keep you informed about further developments in our newsletters and client alerts.

    Authors

    Dr. Matthias Kampshoff

    Partner

    Düsseldorf

    Dr. Uwe Goetker

    Partner

    Düsseldorf

    More insights

  • Employer Concerns — Federal and New York Legislation Responding to COVID-19 (with Chart of Requirements)

    Employer Concerns — Federal and New York Legislation Responding to COVID-19 (with Chart of Requirements)

    ARTICLE / CLIENT ALERT

    Employer Concerns — Federal and New York Legislation Responding to COVID-19 (with Chart of Requirements)

    March 19, 2020

    Read time: 8 min

    Key takeaways
    Overview

    Families First Coronavirus Response Act

    On March 18, 2020, President Trump signed the Families First Coronavirus Response Act into law. The Act will become effective April 2, 2020 and will remain in effect until December 31, 2020. The Act does not apply to employers with 500 or more employees.

    FMLA Expansion for Public Health Emergency

    Section 102(a)(1) of the Family and Medical Leave Act (FMLA) is being temporarily amended to include a new entitlement to leave for employees with a “qualifying need related to a public health emergency.”

    With respect to this addition, the FMLA will now apply to employers with fewer than 500 employees and cover any employee who worked for the employer for at least 30 days prior to the FMLA leave. Small businesses (fewer than 50 employees) are exempt from this provision if the leave would jeopardize the viability of their business.

    Employers will be required to provide up to 12 weeks of leave to employees if they are unable to work (in person or remotely) due to a need to care for a child because the child’s school or child care is unavailable due to a public health emergency. The first 10 days of this emergency FMLA leave may be unpaid. Throughout this initial period, the employee can utilize accrued vacation or sick leave. Starting on the 11th day of the leave, employers generally must pay full-time employees at two-thirds of the employee’s regular rate of pay for the number of hours the employee would otherwise be scheduled to work. Payment is capped at $200 a day (or $10,000 total). Employees who work part-time or irregular schedules would be entitled to payment based on the average number of hours the employee worked for the six months prior to taking the leave.

    Pursuant to this addition, employers with 25 or more employees are required to restore any employee taking leave under the Act to the same or substantially same position they held prior to the leave with equivalent pay and benefits. Employers with fewer than 25 employees do not have to restore an employee to the same position if the position no longer exists after the leave due to economic circumstances caused by a public health emergency and the employer made reasonable attempts to return the employee to an equivalent position.

    Paid Sick Leave

    Employers will be required to provide 80 hours of paid sick-leave benefits if the employee is:

    1. Subject to a federal, state or local quarantine or isolation order related to COVID-19;
    2. Advised by a health care provider to self-quarantine due to COVID-19 concerns;
    3. Experiencing COVID-19 symptoms and seeking medical diagnosis;
    4. Caring for an individual (not limited to family members) subject to quarantine or isolation;
    5. Caring for the employee’s child if the school or child care is unavailable due to a public health emergency; or
    6. Experiencing any other substantially similar condition specified by the Secretary of Health and Human Services.

    COVID-19 Benefits Under Group Health Plans

    The Act also expands benefits under private health plans for COVID-19-related testing and treatment. As discussed in our prior Alert, New York State has already required insurance carriers for fully-insured health plans to waive cost sharing for COVID-19 testing as well any emergency room, urgent care and office visits associated therewith. Such protection, however, applied only to fully-insured health plans. The Families First Coronavirus Response Act now extends these benefits to all private health plans, including self-insured plans. The Act specifically provides that group health plans, including grandfathered health plans under the Patient Protection and Affordable Care Act, and health insurance issuers offering coverage in the individual market, must, as of the date of enactment of the Act, cover FDA-approved testing for COVID-19 and any subsequent treatment thereof without cost sharing (i.e., without deductibles, copayments and coinsurance) or other requirements (e.g., preauthorization).

    Plan sponsors of group health plans should review their plan documents to make sure they are drafted to permit this required coverage, and should notify participants and beneficiaries that any COVID-19-related testing and treatment is now covered under the terms of their plans.

    Tax Credits for Qualified Sick Wages

    The Act provides employers with credits against the taxes imposed on qualified sick wages. Qualified sick wages are wages and compensation paid by an employer as required to be paid by the Act. Qualified sick wages taken into account for purposes of the tax credit cannot exceed:

    • $200 per individual per day of qualified sick leave; or
    • $511 per individual per day of qualified sick leave for individuals who are under a federal, state or local-ordered quarantine related to COVID-19; individuals who are have been advised by a healthcare provider to self-quarantine due to concerns related to COVID-19; or individuals who are experiencing symptoms of COVID-19 and are seeking medical diagnosis.

    The Act also provides employers with credits against taxes imposed on qualified health plan expenses allocated to the qualified sick wages. Qualified health plan expenses are the amounts paid by an employer to maintain a group health plan, but only to the extent that the amounts are excluded from employees’ gross income.

    These tax credits apply to wages and health expenses paid from a date to be selected by the Secretary of the Treasury to Dec. 31, 2020.

    Employers need to adhere to the above requirements within 15 days and provide notice to their employees.

    This federal program will work in coordination with state or local paid leave laws and benefits. Many states are proposing similar emergency legislation in an effort to navigate this rapidly evolving situation.

    New York Sick Leave Law

    In fact, on March 18, 2020, Governor Cuomo signed a bill into law implementing new requirements for New York employers to provide sick leave and other benefits for employees subject to a mandatory or precautionary quarantine or isolation order by a government agency due to COVID-19 (an “Order”).

    COVID-19 Sick Leave

    This law requires that all New York employers must provide unpaid sick leave until the termination of an Order. Certain employers must also provide employees with paid sick leave based on the size of the employer as of Jan. 1, 2020, shown in the chart below. After five days of paid sick leave, or after having exhausted all sick leave provided by their employer pursuant to this law, employees are eligible for short-term disability benefits or paid family leave benefits.

    Employers cannot discharge, threaten, penalize, discriminate or retaliate against employees for taking this sick leave. Employees have a right to return to their position held before the quarantine leave with the same pay and other terms of employment.

    This law does not apply to employees who are asymptomatic or have not been diagnosed with any medical condition and are physically able to work remotely while subject to the Order.

    General Sick Leave

    The law also requires employers to provide employees sick leave with full job protection due to the following for either the employee or the employee’s family member: (i) mental or physical illness; (ii) for the diagnosis, care, or treatment of the mental or physical illness, injury or health condition; and (iii) absence from work related to domestic violence, a sexual offense, stalking, or human trafficking. Employers cannot require disclosure of confidential information relating to the physical or mental illness of the employee or employee’s family member as a condition of sick leave.

    The requirements for leave vary based on the size of the employer the prior calendar year, shown in the chart below. The employer can require that sick leave accrue, but the rate cannot be less than one hour per 30 hours worked. The law provides that unused sick leave be carried over to the following calendar year, although employers with fewer than 100 employees may limit use of sick time to 40 hours per calendar year and employers with 100 or more employees can limit use of sick leave to 56 hours per calendar year.

    The sick leave requirements related to an Order go into effect immediately, whereas the general sick leave requirements go into effect September 14, 2020.

    New York Sick Leave Requirements

    Employer Size
    COVID-19 Sick Leave Requirements
    General Sick Leave Requirements (effective Sept. 14, 2020)

    4 or fewer employees and net income less than $1 million

    –

    40 hours unpaid sick leave per calendar year

    4 or fewer employees and net income greater than $1 million

    –

    40 hours paid sick leave per calendar year

    10 or fewer employees and net income less than $1 million

    Unpaid sick leave until the termination of the Order

    –

    10 or fewer employees and net income greater than $1 million

    5 days paid sick days

    –

    5 to 99 employees

    –

    40 hours paid sick leave per calendar year

    11 to 99 employees

    5 days paid sick days

    –

    100 or more employees

    14 paid sick days

    56 hours paid sick leave per calendar year

     


    Authored by Mark E. Brossman, Ronald E. Richman, Scott A. Gold, Donna K. Lazarus, Melissa J. Sandak, and Michelle M. Orge.

    If you have any questions concerning this Client Alert, please contact your attorney or one of the authors.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Donna K. Lazarus

    Partner

    New York – 919 Third Avenue

    Michelle M. Orge

    Associate

    New York – 919 Third Avenue

    More insights

  • Short-Selling — Update — Austria Bans Short-Selling

    Short-Selling — Update — Austria Bans Short-Selling

    ARTICLE / CLIENT ALERT

    Short-Selling — Update — Austria Bans Short-Selling

    19 March 2020

    Read time: 2 min

    Key takeaways
    Overview

    The Austrian Financial Market Authority has announced a ban on short sales, including creating or increasing net short positions via derivatives or other financial instruments which confer a financial advantage in the event of the decrease in the price of the covered stocks. The ban covers all shares admitted to trading on the Vienna Stock Exchange (Wiener Börse) and will remain in effect until 18 April 2020. Short sales of equity indices or baskets are covered by the ban if the restricted securities account for 50% or more of their composition. FMA’s announcement is available here.

    The Austrian emergency measures follow the bans introduced earlier this week by the regulators in Belgium, France, Greece and Spain.

    Authored by Anna Maleva-Otto and Brian T. Daly.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • Litigation Alert — Force Majeure Under New York and Delaware Law

    Litigation Alert — Force Majeure Under New York and Delaware Law

    ARTICLE / CLIENT ALERT

    Litigation Alert — Force Majeure Under New York and Delaware Law

    March 19, 2020

    Read time: 13 min

    Key takeaways
    Overview

    In a matter of weeks, the COVID-19 outbreak has brought much of the world to a standstill. With the sudden economic decline and government-mandated restrictions now in place, some businesses will find themselves unable to comply with their contractual obligations. Any business anticipating its own — or a counterparty’s — inability to comply with contract responsibilities due to COVID-19 should be familiar with how force majeure and other aspects of contract law may apply to them during this global pandemic.[1] Insurance policies covering business interruptions should also be assessed.

    Force Majeure Provisions

    A force majeure is an unanticipated event (for simplicity, this Alert will refer to it as the “event”) beyond the control of the contracting parties that makes it impracticable or impossible for a party to fulfill its responsibilities and obligations, and may excuse a party from performing under a contract.[2]

    Businesses should look for the presence of — and any limitations on — force majeure provisions in any contracts they anticipate that they or their counterparty will struggle to fulfill as a result of the outfall from COVID-19. Those provisions typically require the disabling event to be unforeseeable to both parties, and sometimes specify certain types of events that are per se unforeseeable, such as, for example, earthquakes, acts of terrorism and sometimes epidemics or pandemics.

    Since the World Health Organization declared COVID-19 a “pandemic” on March 11, 2020, force majeure clauses that expressly include “pandemics” will likely be triggered.[3] Other contractual language regarding viral outbreaks, epidemics, or governmental prohibitions may also trigger the clause.[4]

    Even if COVID-19 falls within the scope of a force majeure provision, the event must objectively affect the parties’ ability to perform.[5] Accordingly, a party seeking to invoke a force majeure clause to excuse its nonperformance must show that the event directly caused performance to be impossible or unreasonably expensive in spite of its skill, diligence, and good faith.[6] Again, the language of the contract will dictate the application, effect and scope of a force majeure clause.[7]

    Force majeure provisions may have specific application in particular types of contracts. For more information on some of these specific applications please see the following SRZ Alerts: Real Estate Deals and Leases — COVID-19 Considerations (March 17, 2020) (discussing “go-dark” and material adverse effect provisions in leases and other real estate agreements), Trading Agreements — Buy-Side Considerations (COVID-19) (March 17, 2020) (discussing force majeure and related provisions in trading agreements, including ISDA master agreements, prime brokerage agreements, master repurchase agreements, futures agreements and FX master agreements), SRZ Alert on Business Interruption and Related Insurance for Losses from COVID-19 (March 17, 2020) (outlining business interruption insurance and other insurance related to loss).

    What If There Is No Force Majeure Clause?

    Even without a force majeure clause, performance may still be excused if a party cannot meet its obligations due to COVID-19. Generally, a party has no duty to perform under a contract if performance becomes impossible or in some jurisdictions impracticable.[8] “Impossible” and “impractical” are legal standards. Courts may conclude that performance is impracticable when it can only be accomplished at an excessive, unreasonable, and unbargained-for cost,[9] or impossible when a party cannot perform due to circumstances beyond that party’s control.[10] Similarly, the legal doctrine of frustration of purpose excuses nonperformance in certain situations where the objectives of the contract have been utterly defeated by circumstances arising after the formation of the agreement.[11] Finally, contracts sometimes require the parties to comply with the laws, orders, rules, regulations and requirements of governmental authorities, which also may excuse performance in the face of the many directives being issued for purposes of public health, as well as economic and financial stability.[12]

    In the face of the substantial business disruptions that have occurred in the wake of COVID-19, counterparties may seek to renegotiate contracts or reach accommodations in light of longer-term business interests or to avoid the uncertainty of the application of the aforementioned legal doctrines.      

    Insurance Considerations

    The same circumstances that have made performance of contractual obligations impossible have created massive disruptions in businesses’ normal operations, but certain types of insurance may help. Business interruption, use and occupancy, and other similar policies may cover losses caused by the insured’s inability to continue normal business operations after losing the ability to use specified property or premises.[13] For more information about insurance for losses relating to COVID-19, please see SRZ’s Alert, Business Interruption and Related Insurance for Losses from COVID-19 (March 17, 2020).

    The full impact of COVID-19 on economies and businesses around the world is still uncertain. However, clients should familiarize themselves with the aforementioned contract and insurance doctrines. We will continue to closely monitor this public health crisis and the potential effects it could have on our client’s businesses. Should you have any questions about the concepts explored in this Alert or other questions about your business in light of COVID-19 please contact your attorneys at Schulte Roth & Zabel or one of the authors.

    Authored by William H. Gussman, Jr., Douglas I. Koff, Michael E. Swartz, Kelly Koscuiszka, Brooke Y. Oki and Katherine M. Sullivan.


     

    [1] COVID-19 effects may also trigger material adverse change provisions in M&A contracts and in other contexts. See, e.g., “Deal Terms — Assessing Material Adverse Change Clauses and Other Deal Certainty Considerations Under and After COVID-19,” SRZ Alert, March 16, 2020, available here.

    [2] GLEN BANKS, 28A NEW YORK PRACTICE SERIES-NEW YORK CONTRACT LAW § 20:13 Force majeure (2d ed. 2019).

    [3] Betsy McKay, Jennifer Calfas and Talal Ansari, Coronavirus Declared Pandemic by World Health Organization, Wall Street J. (Mar. 11, 2020, 11:59pm); see also Akorn, Inc. v. Fresenius Kabi AG, No. CV 2018-0300-JTL, 2018 WL 4719347, at *51 (Del. Ch. Oct. 1, 2018), aff’d, 198 A.3d 724 (Del. 2018) (Clause listed “pandemics, earthquakes, floods, hurricanes, tornados or other natural disasters, weather-related events, force majeure events or other comparable events. . .”).

    [4] Duane Reade v. Stoneybrook Realty, LLC, 63 A.D.3d 433, 434 (1st Dep’t 2009).

    [5] Glen Banks, 28A New York Practice Series-New York Contract Law § 20:13 Force majeure (2d ed. 2019).

    [6] Richard A. Lord, 30 Williston on Contracts § 77:31.Force Majeure clauses, (4th ed. 2019).

    [7] Constellation Energy Servs. of New York, Inc. v. New Water St. Corp., 146 A.D.3d 557, 558 (1st Dep’t 2017).

    [8] Richard A. Lord, 30 Williston on Contracts § 77:31.Force Majeure clauses, (4th ed. 2019).

    [9] Id.

    [10] Freedman v. Hason, 155 A.D.3d 831, 833 (2d Dep’t 2017) (“‘[T]he impossibility must be produced by an unanticipated event that could not have been foreseen or guarded against in the contract’”) (quoting Kel Kim Corp. v. Central Mkts., 70 N.Y.2d 900, 902 (1987)).

    [11] Richard A. Lord, 30 Williston on Contracts § 77:31.Force Majeure clauses, (4th ed. 2019); Restatement (Second) of Contracts ch. 11, § 266 Existing Impracticability or Frustration (Am. Law Inst. 1981) (October 2019 update).

    [12] Tracy Batemen et al., 77A Corpus Juris Secundum, Sales § 370 (2020) (“Force majeure provisions generally have the effect of excusing nonperformance arising out of certain causes, as, for instance, acts of God, acts of a public enemy, acts of the United States government.”); see also, Castor Petroleum v. Petroterminal De Panama, 107 A.D.3d 497, 498 (1st Dep’t 2013) (Government’s restrictive court order fell into the agreement’s broad force majeure provision which included, among other things, a ‘government embargo or interventions or other similar or dissimilar event or circumstances’.)

    [13] Steven Pitt et al., 11A Couch on Insurance § 167:11.Generally; need for “loss”, (3rd ed. 2019).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    William H. Gussman Jr.

    Partner

    New York – 919 Third Avenue

    Douglas I. Koff

    Partner

    New York – 919 Third Avenue

    Kelly Koscuiszka

    Partner

    New York – 919 Third Avenue

    More insights

  • ERISA Considerations for Investment Managers — COVID-19 and Volatile Markets

    ERISA Considerations for Investment Managers — COVID-19 and Volatile Markets

    ARTICLE / CLIENT ALERT

    ERISA Considerations for Investment Managers — COVID-19 and Volatile Markets

    March 19, 2020

    Read time: 7 min

    Key takeaways
    Overview

    Among the many challenges and issues to be addressed by investment managers in connection with COVID-19, investment managers must not lose sight of the specific issues that arise under the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

    Please see our other SRZ Alerts relevant to investment managers posted on our COVID-19 Resource Center. See our Alert for tax issues raised or exacerbated by current market conditions and buying opportunities, available here, our Alert on cybersecurity, available here, our various Alerts on regulatory updates and our Alert on considerations for private equity fund sponsors, available here.

    25% Test

    ERISA issues can arise regardless of whether a fund is intended to be subject to ERISA (i.e., because 25% or more of the NAV of any class of equity in the fund is owned by U.S. private pension plans, IRAs and fund-of-funds whose underlying investors are heavily U.S. private pension plans and IRAs, so called “benefit plan investors”) or the fund is intended not to be subject to ERISA (i.e., because the fund restricts ownership of each class of equity interests by benefit plan investors to less than 25%).

    Subscriptions and Redemptions

    1. Under ERISA, each time there is a subscription or redemption from a fund, the investment manager is required to recalculate the benefit plan investor percentage of the NAV for each class of equity in the fund.
    2. If the fund’s offering material (or a side letter) commits to limiting investment by benefit plan investors to less than 25% of each class of equity of the fund, then withdrawals must be handled in a manner that preserves that commitment (e.g., by compulsory redeeming benefit plan investors to maintain the 25% ratio or by suspending redemptions).

    Fund Restructuring

    1. The 25% test also must be run in connection with various forms of fund restructuring.
    2. If restructuring bifurcates the fund’s investments disproportionately among its investors (i.e., so that not all investors share in the same portfolio), ERISA’s 25% test must be applied to each separate portfolio, on a class-by-class basis, as if it were a separate entity (regardless of whether an actual legally separate entity is created).

    New SPVs

    1. If restructuring involves the transfer of assets to a new SPV, ERISA’s 25% test must be applied to the SPV, on a class-by-class basis.
    2. If the underlying fund committed to limit investment by benefit plan investors to less than 25% of each class of equity of the fund, the SPV must also impose that limitation on benefit plan investors.

    Side Pockets

    1. If a fund’s portfolio is not totally bifurcated but certain assets are side pocketed, ERISA’s 25% test must be applied separately to each side pocket as if it were a deemed separate entity, as well as the main fund.
    2. If a fund complies with the 25% test when the side pocket is established and investors’ ownership of the side pocket is proportionate to their ownership in the main fund, the side pocket should also meet the 25% test.
    3. If the investors’ ownership of the side pocket is not proportionate to their ownership in the main fund — likely because investors are given opt-in/opt-out rights — then the side pocket may not meet with the 25% test. For example, if too many non-benefit plan investors opt out of the side pocket versus benefit plan investors that opt in, the ownership percentage by benefit plan investors will increase, potentially causing the side pocket not to meet the 25% test. To address this potential risk, side-pocket election forms should provide that an investor’s election will be implemented, to the fullest extent possible, but subject to the need of the side pocket to meet the 25% test.

    New Classes

    1. If a fund chooses to deal, in whole or in part, with dislocations caused by the current economic situation by creating a new class or classes of equity with different liquidity terms than the existing classes, the 25% test must be rerun taking into account the investors in each equity class (both the old classes that still exist and any new class of shares).
    2. If the fund committed to limit investment by benefit plan investors to less than 25% of each class of equity of the fund, the fund must ensure that benefit plan investors continue to own less than 25% of each equity class.

    Redemptions

    1. If a fund adopts a “slow pay mechanism” to effect redemptions, the portion of the fund consisting of slow pay assets may be deemed for purposes of ERISA’s 25% test as a separate entity.
    2. If the fund committed to limit investment by benefit plan investors to less than 25% of each class of equity of the fund, the fund must ensure that that the portion of the fund consisting of the slow pay assets meets the 25% test by monitoring which investors redeem on a specific redemption date.

    Master-Feeder Structures

    1. With respect to a master-feeder structure where the feeder assets are “hard wired”[1] into a master fund that is designed to meet the 25% test, any actions, such as a restructuring, should ensure that the master fund continues to meet the 25% test.

    ERISA Plan Asset Funds

    The 25% test should not be a concern if a fund has been designed to hold plan assets (commonly called, “plan asset fund”) and comply with ERISA’s requirements (i.e., because the fund does not limit investment by benefit plan investors to meet the 25% test). However, in the context of the rapid actions that might be made during the quickly evolving financial market, managers of plan asset funds must continue to ensure their compliance with ERISA.

    1. Any restructuring involving a plan asset fund must ensure compliance with ERISA fiduciary duties — such as prohibitions on conflict of interest transactions.
    2. Managers of plan asset funds must be mindful of possible conflict of interest issues that can arise where investments made by a side pocket, SPV or new fund “face off” against the main fund or another fund managed by the manager.
    3. Any conflicts that may arise must be resolved in a manner that is ERISA compliant and disclosures should be made in the new fund’s offering documents.

    Authored by David M. Cohen and Ian L. Levin.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] In that situation the feeder (typically the offshore feeder) is permitted to allow investment by benefit plan investors to exceed 25% of a class of equity in the feeder as long as benefit plan investment in the feeder does not cause the master fund to violate the 25% limitation. 


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    David M. Cohen

    Partner

    New York – 919 Third Avenue

    Ian L. Levin

    Partner

    New York – 919 Third Avenue

    More insights

  • CFTC Update: Limited Relief on Uncleared Margin Requirements

    CFTC Update: Limited Relief on Uncleared Margin Requirements

    ARTICLE / CLIENT ALERT

    CFTC Update: Limited Relief on Uncleared Margin Requirements

    March 19, 2020

    Read time: 3 min

    Key takeaways
    Overview

    On March 18, 2020, the Commodity Futures Trading Commission voted to adopt a final rule granting a one-year extension for swap margin compliance by financial entities with smaller swaps portfolios. The compliance schedule deadline for posting and collection of initial margin by covered swap entities under “Phase 5” of the compliance schedule had been Sept. 1, 2020 (i.e., for swap market participants with between $8 billion global and $750 billion global of swap notional amounts).

    In the new rule, the CFTC created a new Phase 6 for entities with the smallest uncleared swap portfolios (i.e., financial end users that have average daily aggregate notional amounts of less than $50 billion global). The new deadline for Phase 6 will be Sept. 1, 2021 (the Sept. 1, 2020 deadline will remain in place for any Phase 5 entities not covered by the new rule).

    Private fund managers and other parties to swap agreements eligible for Phase 6 compliance should note that:

    • The extension in the final rule only applies to initial margin requirements, and only covers estimated potential futures exposures; and
    • The final rule does not change current variation margin requirements.

    Commissioners noted that providing more time to these smaller swap users will help these market participants in maintaining their hedging capabilities while they negotiate necessary margining agreements.

    Authored by Craig Stein and Atul Joshi.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Craig Stein

    Partner

    New York – 919 Third Avenue

    More insights

  • Tax Update: Certain April 15 Federal Income Tax Payments Delayed for 90 Days (COVID-19)

    Tax Update: Certain April 15 Federal Income Tax Payments Delayed for 90 Days (COVID-19)

    ARTICLE / CLIENT ALERT

    Tax Update: Certain April 15 Federal Income Tax Payments Delayed for 90 Days (COVID-19)

    March 19, 2020

    Read time: 3 min

    Key takeaways
    Overview

    On March 18, 2020, the Internal Revenue Service published Notice 2020-17 (“Notice”) permitting noncorporate taxpayers to delay until July 15, 2020, without interest or penalties, up to $1 million of Federal income tax payments otherwise due on April 15, 2020.[1] This relief applies to tax payments in respect of 2019 and estimated tax payments for the first quarter of 2020, including payments on self-employment income. The Notice similarly allows corporate taxpayers to delay up to $10 million of Federal income tax payments due on April 15, 2020, until July 15, 2020.

    This relief is limited to Federal income tax. Therefore, taxpayers would need separate relief to defer payment of state taxes and other Federal taxes (e.g., withholding taxes) due on April 15, 2020.

    The Notice also does not provide any relief with respect to tax filing obligations due on April 15, 2020.[2] Accordingly, absent additional relief, individual and corporate taxpayers must file their 2019 tax return by April 15, 2020 or obtain an extension by such date. Taxpayers who defer tax payments in excess of the $1 million or $10 million limit will accrue interest and penalties only on such excess. Estimated tax payments for the second quarter of 2020 have not been delayed and, absent future guidance, remain due on June 15, 2020.

    Please contact your attorney at Schulte Roth & Zabel at your earliest convenience if you wish to discuss this notice.


    [1] Married individuals filing jointly are limited to the same $1 million cap to which single taxpayers are subject.

    [2] There are ongoing efforts in the United States Congress to enact legislation which would include delaying tax filing obligations due on April 15, 2020 until July 15, 2020 and increasing the deferral of Federal income tax payments in excess of the $1 million/$10 million limit mentioned above.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • IRS Provides Some Relief from Tax Payment (But Not Filing) Deadlines Due to COVID-19

    IRS Provides Some Relief from Tax Payment (But Not Filing) Deadlines Due to COVID-19

    ARTICLE / CLIENT ALERT

    IRS Provides Some Relief from Tax Payment (But Not Filing) Deadlines Due to COVID-19

    March 18, 2020

    Read time: 3 min

    Key takeaways
    Overview

    On March 13, President Trump issued an emergency declaration that directed Secretary Mnuchin to provide appropriate relief from tax payment deadlines to Americans who have been adversely affected by the COVID-19 pandemic. We outline the specifics.

    In depth

    On March 13, 2020, President Trump issued an emergency declaration that directed Secretary Mnuchin to provide appropriate relief from tax payment deadlines to Americans who have been adversely affected by the COVID-19 pandemic. Today, in response to this direction, the IRS issued Notice 2020-17. The Notice declares that all taxpayers have been affected by the emergency and gives all taxpayers an extension of time until July 15, 2020, to make certain income tax payments that would otherwise have been due on April 15, 2020.

    Here are the specifics:

    1. Individuals may defer payment of up to $1 million worth of income taxes that would have been due on April 15, including estimated income taxes on 2020 income and income taxes due on April 15 with respect to 2019 income. The notice is ambiguous as to whether married individuals share a single $1 million deferral amount, particularly if they file joint returns.
    2. Corporations may defer payment of up to $10 million worth of income taxes that would otherwise be due on April 15.
    3. The extension does not apply to other federal tax payments due on April 15 such as federal gift taxes.
    4. The extension does not apply to the filing of tax returns or information returns. The due date for filing individual tax returns for 2019 remains April 15, 2020. As in other years, taxpayers who want an extension of time for filing their tax returns should file the appropriate form for obtaining extensions no later than April 15, 2020.

    For more information about the tax impact of the COVID-19 emergency declaration, see our prior On the Subject.

    Authors

    Carlyn S. McCaffrey

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • CMS Guidance and Waivers for MA and Part D Plans’ Response to COVID-19

    CMS Guidance and Waivers for MA and Part D Plans’ Response to COVID-19

    ARTICLE / CLIENT ALERT

    CMS Guidance and Waivers for MA and Part D Plans’ Response to COVID-19

    March 18, 2020

    Read time: 4 min

    Key takeaways
    Overview

    Over the past week, the Centers for Medicare & Medicaid Services (CMS) has made a number of announcements related to Medicare coverage in connection with the Coronavirus (COVID-19) outbreak.  Several of those announcements have been specific to Medicare Advantage and Part D. 

    In depth

    Medicare Advantage Organizations

    Regulations Disasters and Emergencies. Pursuant to 42 CFR § 422.100(m), “special requirements” go into effect for Part A/B and supplemental Part C benefit access during disasters and emergencies, including state declarations of emergency and a presidential declaration under the Stafford Act.

    While in effect, these special requirements are that MA Plans must:

    • Cover Medicare Parts A and B services and supplemental Part C benefits at non-contracted facilities subject to § 422.204(b)(3)’s requirements that facilities have participation agreements with Medicare
    • Waive requirements for gatekeeper referrals
    • Provide the same cost-sharing for enrollees as if the service was furnished at a plan-contracted facility
    • Make changes that benefit enrollees effective immediately, without the 30-day notification requirement at § 422.111(d)(3).

    Cost-Sharing Waivers and Telehealth. In a March 10 memo, CMS also advised Medicare Advantage Organizations (MAOs) of additional flexibilities for MAOs through the exercise of CMS’s enforcement discretion.

    • MAOs may waive or reduce enrollee cost-sharing for COVID-19-related services, such as laboratory tests, telehealth benefits or other services to address the outbreak, as long as they do so consistently for all affected enrollees.
    • MAOs may provide enrollees access to Medicare Part B services via telehealth in any geographic area and from beneficiaries’ homes. This flexibility is irrespective of the scope of the telehealth benefit the MA plan filed and CMS approved.
    • On March 17, 2020, CMS issued waivers and guidance to provide Medicare coverage of telehealth. These waivers appear to describe FFS Medicare coverage, and do not directly mention or address any requirements for Medicare Advantage plans.

    CMS noted that it had consulted with the Office of Inspector General (OIG), and that plans that utilized these flexibilities would satisfy the safe harbor to the federal anti-kickback statute set forth at 42 CFR § 1001.952(l). Once the outbreak has subsided, CMS will notify MAOs and Part D sponsors through the Health Plan Management System that CMS is ending its enforcement discretion with respect to such measures.

    Section 1135 Waivers. The Secretary issued a Section 1135 waiver providing that CMS may authorize Medicare administrative contractors to pay for Part C covered services and seek reimbursement from MAOs for those services retrospectively.

    On March 13, CMS waived and modified requirements related to Medicare Advantage appeals and grievances.

    Part D Sponsors

    Expectations and Authorities. The March 10 memo also reminded Part D sponsors of provisions contained in the Prescription Drug Benefit Manual to ensure adequate emergency access for enrollees:

    • Part D sponsors are expected to relax their “refill-too-soon” edits if necessary to ensure access to covered Part D drugs.
    • If enrollees cannot reasonably be expected to obtain covered Part D drugs at a network pharmacy, sponsors must ensure that such enrollees have adequate access to covered Part D drugs dispensed at out-of-network pharmacies, although enrollees will remain responsible for any cost sharing and additional charges that exceed the plan allowance, as applicable.
    • For enrollees that cannot physically access a retail pharmacy (e.g., because of a quarantine), Part D sponsors may relax any plan-imposed policies that would discourage certain methods of delivery, such as mail or home delivery, for retail pharmacies that provide such services
    • In the event that Part D drugs are identified to treat or prevent COVID-19, Part D sponsors may waive prior authorization, as long as they do so consistently.
    • If a vaccine becomes available for COVID-19, Part D plans will be required to cover the vaccine if it is a Part D drug. Otherwise, it will be covered under Medicare Part B.
    Authors

    Jeremy Earl

    Partner

    Washington, DC

    George Tzanetakos

    Partner

    Chicago

    More insights